Molecular Endocrinology, Vol 10, 477-487, Copyright © 1996 by Endocrine Society

ARTICLES

Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor-alpha 1 promoter via a novel sequence

MG Elgort, A Zou, KB Marschke and EA Allegretto
Department of Retinoid Research, Ligand Pharmaceuticals, Inc. San Diego, California 92121, USA.

We and others previously reported that up-regulation of retinoic acid receptor-alpha (RAR alpha) RNA and protein levels is elicited by estrogen in human breast cancer cells. We set out to determine the mechanism by which estrogen up-regulates RAR alpha. Cloning of 500 bp of the human (h) RAR alpha 1 promoter has been reported previously; we obtained this 500-bp DNA sequence by PCR techniques from human genomic DNA and tested its activity in the context of a luciferase-containing reporter vector in Hep G2 cell contransactivation assays. Estradiol elicited a 6- to 8-fold increase in luciferase activity from the reporter vector driven by hRAR alpha promoter sequence between -491 and +36 bp that was dependent on the presence of contransfected estrogen receptor (ER). Analysis of various truncated versions of this promoter sequence indicated that two regions of the sequence are sensitive to estrogen stimulation. The first resides in the region -49 to -79 bp upstream from the transcription start site and conferred approximately 2-fold activation by estrogen. This region does not contain a consensus estrogen response element, and ER binding to this DNA sequence was not observed. The second responsive sequence lies at -455 to -491 bp and conferred in additional 4- to 6-fold activation by estrogen. This upstream sequence contains two A/TGGTCA half-sites; however, direct binding of ER to this sequence was not observed. Additionally, ER DNA- binding domain mutants that are not capable of binding to DNA were just as effective as wild type ER in their ability to confer estrogen responsiveness to the RAR alpha promoter, implying that ER DNA-binding ability is not required for the estrogen-induced increase in transcriptional activity. Mutation of either half-site or of an additional immediate downstream sequence in the context of the -491 to +36 bp construct reduced the luciferase activity induction by estrogen from 6-fold to 1.5- to 2-fold. Placement of the region between -455 to - 491 bp upstream of an SV40 promoter-driven luciferase vector conferred approximately 20- to 30-fold stimulation of luciferase activity by estrogen in an ER-dependent manner. The ER antagonists, 4-hydroxy- tamoxifen, keoxifene, and ICI 164384, each acted as weak agonist via the hRAR alpha promoter in contransactivation assays, exhibiting 20-30% of the efficacy that was demonstrated by estradiol. Interestingly, upon treatment of MCF7 cells with estradiol or the ER antagonists, increased levels of RAR alpha RNA and protein were observed with the antagonists as well as with estrogen.

This article has been cited by other articles:

				K. M. M. Kelley, B. G. Rowan, and M. Ratnam Modulation of the Folate Receptor {alpha} Gene by the Estrogen Receptor: Mechanism and Implications in Tumor Targeting Cancer Res., June 1, 2003; 63(11): 2820 - 2828. [Abstract] [Full Text] [PDF]

				L. C. Hodges, J. D. Cook, E. K. Lobenhofer, L. Li, L. Bennett, P. R. Bushel, C. M. Aldaz, C. A. Afshari, and C. L. Walker Tamoxifen Functions As a Molecular Agonist Inducing Cell Cycle-Associated Genes in Breast Cancer Cells Mol. Cancer Res., February 1, 2003; 1(4): 300 - 311. [Abstract] [Full Text] [PDF]

				P. Yi, S. Bhagat, R. Hilf, R. A. Bambara, and M. Muyan Differences in the Abilities of Estrogen Receptors to Integrate Activation Functions Are Critical for Subtype-Specific Transcriptional Responses Mol. Endocrinol., August 1, 2002; 16(8): 1810 - 1827. [Abstract] [Full Text] [PDF]

				X.-H. Li, H. Li, Z.-J. Xiao, and Y.-S. Piao Divergent Effects of Retinoic Acids on the Expression of ER{alpha} and 17{beta}-Hydroxysteroid Dehydrogenase Type 2 in Endometrial Carcinoma Cells (RL 95-2) J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 640 - 649. [Abstract] [Full Text] [PDF]

				S. Wissink, B. van der Burg, B. S. Katzenellenbogen, and P. T. van der Saag Synergistic Activation of the Serotonin-1A Receptor by Nuclear Factor-{{kappa}}B and Estrogen Mol. Endocrinol., April 1, 2001; 15(4): 543 - 552. [Abstract] [Full Text]

				M. E. Quaedackers, C. E. Van Den Brink, S. Wissink, R. H. M. M. Schreurs, J.-A. Gustafsson, P. T. Van Der Saag, and B. Van Der Burg 4-Hydroxytamoxifen Trans-Represses Nuclear Factor-{{kappa}}B Activity in Human Osteoblastic U2-OS Cells through Estrogen Receptor (ER){{alpha}}, and Not through ER{{beta}} Endocrinology, March 1, 2001; 142(3): 1156 - 1166. [Abstract] [Full Text] [PDF]

				P. S. Jones, E. Parrott, and I. N. H. White Activation of Transcription by Estrogen Receptor alpha and beta Is Cell Type- and Promoter-dependent J. Biol. Chem., November 5, 1999; 274(45): 32008 - 32014. [Abstract] [Full Text] [PDF]

				P. Webb, P. Nguyen, C. Valentine, G. N. Lopez, G. R. Kwok, E. McInerney, B. S. Katzenellenbogen, E. Enmark, J.-A. Gustafsson, S. Nilsson, et al. The Estrogen Receptor Enhances AP-1 Activity by Two Distinct Mechanisms with Different Requirements for Receptor Transactivation Functions Mol. Endocrinol., October 1, 1999; 13(10): 1672 - 1685. [Abstract] [Full Text]

				W. Khovidhunkit and D. M. Shoback Clinical Effects of Raloxifene Hydrochloride in Women Ann Intern Med, March 2, 1999; 130(5): 431 - 439. [Abstract] [Full Text] [PDF]

				A. Zou, K. B. Marschke, K. E. Arnold, E. M. Berger, P. Fitzgerald, D. E. Mais, and E. A. Allegretto Estrogen Receptor {beta} Activates the Human Retinoic Acid Receptor {alpha}-1 Promoter in Response to Tamoxifen and Other Estrogen Receptor Antagonists, but Not in Response to Estrogen Mol. Endocrinol., March 1, 1999; 13(3): 418 - 430. [Abstract] [Full Text]

				M. D. Driscoll, G. Sathya, M. Muyan, C. M. Klinge, R. Hilf, and R. A. Bambara Sequence Requirements for Estrogen Receptor Binding to Estrogen Response Elements J. Biol. Chem., November 6, 1998; 273(45): 29321 - 29330. [Abstract] [Full Text] [PDF]

				H.-L. C. Liu, E. Golder-Novoselsky, M. H. Seto, L. Webster, J. McClary, and D. A. Zajchowski The Novel Estrogen-Responsive B Box Protein (EBBP) Gene Is Tamoxifen Regulated in Cells Expressing an Estrogen Receptor DNA-Binding Domain Mutant Mol. Endocrinol., November 1, 1998; 12(11): 1733 - 1748. [Abstract] [Full Text]

				G. Sun, W. Porter, and S. Safe Estrogen-Induced Retinoic Acid Receptor {alpha}1 Gene Expression: Role of Estrogen Receptor-Sp1 Complex Mol. Endocrinol., June 1, 1998; 12(6): 882 - 890. [Abstract] [Full Text]

				J. D. Norris, D. Fan, M. R. Stallcup, and D. P. McDonnell Enhancement of Estrogen Receptor Transcriptional Activity by the Coactivator GRIP-1 Highlights the Role of Activation Function 2 in Determining Estrogen Receptor Pharmacology J. Biol. Chem., March 20, 1998; 273(12): 6679 - 6688. [Abstract] [Full Text] [PDF]

				S. Petersenn, A. C. Rasch, M. Heyens, and H. M. Schulte Structure and Regulation of the Human Growth Hormone-Releasing Hormone Receptor Gene Mol. Endocrinol., February 1, 1998; 12(2): 233 - 247. [Abstract] [Full Text]

				G. E. Croston, L. B. Milan, K. B. Marschke, M. Reichman, and M. R. Briggs Androgen Receptor-Mediated Antagonism of Estrogen-Dependent Low Density Lipoprotein Receptor Transcription in Cultured Hepatocytes Endocrinology, September 1, 1997; 138(9): 3779 - 3786. [Abstract] [Full Text] [PDF]

				A. Zou, M. G. Elgort, and E. A. Allegretto Retinoid X Receptor (RXR) Ligands Activate the Human 25-Hydroxyvitamin D3-24-hydroxylase Promoter via RXR Heterodimer Binding to Two Vitamin D-responsive Elements and Elicit Additive Effects with 1,25-Dihydroxyvitamin D3 J. Biol. Chem., July 25, 1997; 272(30): 19027 - 19034. [Abstract] [Full Text] [PDF]

				J. D. Norris, D. Fan, S. A. Kerner, and D. P. McDonnell Identification of a Third Autonomous Activation Domain within the Human Estrogen Receptor Mol. Endocrinol., June 1, 1997; 11(6): 747 - 754. [Abstract] [Full Text]